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Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease characterized
by a progressive cognitive decline associated with global brain damage. Initially,
intracellular paired helical filaments composed by hyperphosphorylated tau and
extracellular deposits of amyloid-β (Aβ) were postulated as the causing factors of the
synaptic dysfunction, neuroinflammation, oxidative stress, and neuronal death, detected
in AD patients. Therefore, the vast majority of clinical trials were focused on targeting Aβ
and tau directly, but no effective treatment has been reported so far. Consequently, only
palliative treatments are currently available for AD patients. Over recent years, several
studies have suggested the involvement of the purinergic receptor P2X7 (P2X7R), a
plasma membrane ionotropic ATP-gated receptor, in the AD brain pathology. In this line,
altered expression levels and function of P2X7R were found both in AD patients and AD
mouse models. Consequently, genetic depletion or pharmacological inhibition of P2X7R
ameliorated the hallmarks and symptoms of different AD mouse models. In this review,
we provide an overview of the current knowledge about the role of the P2X7R in AD.
Keywords: amyloidogenic processing, inflammation, oxidative stress, synaptopathy, microglia, induced
pluripotent stem cells
HIGHLIGHTS
- Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder.
- P2X7R is upregulated in AD.
- P2X7R is involved in microglial function, synaptopathy, oxidative stress, and
amyloidogenic APP processing.
- Induced pluripotent stem cell (iPSC) is a promising new therapeutic approach in AD.
ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder currently affecting more than
47 million people around the world, expecting to reach more than 131 million by 2050. Typical
AD onset is after 65 years old, although in less than 5% of cases, onset may be earlier (Alzheimer’s-
Association, 2019). Approximately between 1 and 3% of AD patients present autosomal dominant
form of AD, denominated early familiar AD (eFAD) (Price and Sisodia, 1998). This form is
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characterized by mutations in both amyloid-β (Aβ) precursor
protein (APP) and enzymes related in its processing, like
presenilin-1 and presenilin-2 (PSEN1 and PSEN2) (Price and
Sisodia, 1998; Ling et al., 2003).
Symptoms associated to AD follow a progressive course,
starting with an impairment in learning and memory,
proceeding to later detriments in complex attention, executive
functions, language, visuospatial compartment, praxis, gnosis,
behavior, and/or social compartment (McKhann et al., 2011). At
neuropathological level, postmortem brains from AD patients
show atrophy of frontotemporal cortex and hippocampus
caused by neuronal loss, neuroinflammation, loss of synapses,
and oxidative stress. Typical hallmarks of AD are extracellular
senile plaques and intracellular neurofibrillary tangles (NFTs)
(Gahtan and Overmier, 1999; Selkoe, 2001; Avila, 2006; Perl,
2010). Senile plaques are formed by β-amyloid Aβ peptides,
generated by the sequential proteolysis of APP by β-secretase
1 (BACE1) and γ-secretase (PSEN1 and 2, Nicastrin, and
APH-1) (Selkoe, 2001). NFTs are assembled by abnormal
accumulation of hyperphosphorylated tau protein [microtubule
associated protein tau (MAPT)] (Avila, 2006). Aβ peptide and
phosphorylated Tau protein, primary criteria for AD diagnosis,
are considered the main toxic species involved in AD (Long and
Holtzman, 2019). Indeed, detection of Aβ and tau deposition
in cerebrospinal fluid (CSF) or positron emission tomography
(PET) imaging presents now an antemortem AD neuropathology
diagnosis (Bridel et al., 2019; Lowe et al., 2019).
Current Therapeutic Strategies in AD
There are only four commercial palliative-treatments available
for symptomatic AD patients: three acetylcholinesterase
inhibitors (donepezil, rivastigmine, galantamine) and
memantine, a non-competitive NMDA receptors modulator
(Long and Holtzman, 2019). Despite all efforts made, there is
no effective treatment available for symptomatic AD patients.
Over the last decade, numerous clinical trials have been carried
out to avoid the amyloid toxicity associated with AD. One of
those was focused on developing specific monoclonal antibodies
against Aβ, both soluble and fibrillar forms (Doody et al.,
2013; Salloway et al., 2014; Selkoe, 2019) or try to induce
an active immunization. Other strategies have attempted
to reduce brain Aβ burden designing new potent secretase
inhibitors, both against γ-secretase or BACE1 inhibitors (Egan
et al., 2018, 2019; Henley et al., 2019; Lopez Lopez et al.,
2019). Another trial used anti-inflammatory drugs to avoid
Aβ-induced neuroinflammation, focusing on the inhibition
of the cyclooxygenase enzyme (Aisen et al., 2000; de Jong
et al., 2008). Since some studies have shown increased levels
of cholesterol promoting the production of Aβ, other clinical
trials used statins likes hydroxymethylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors as cholesterol-lowering
agents (Carlsson et al., 2008; Feldman et al., 2010). Regarding
Tau-based clinical trials, the followed strategies have been
focused on reducing its intracellular phosphorylation rate
(Domínguez et al., 2012), avoiding its aggregation (Wischik
et al., 1996, 2015), or allowing its removal using immunotherapy
approaches. Tau immunotherapy is based on both active and
passive immunization approaches. Active immunization must
be handled carefully, avoiding the pathogenic activation of the
immune system, in particular T-cells, that could lead to aseptic
meningo-/encephalitis endangering patient safety. In contrast,
passive immunotherapy provides the advantage of control over
antibodies’ binding properties and their blood concentrations
(Vogels et al., 2019). So far, nine ongoing immunotherapy studies
are being reported (Alzforum, 2019), two of which are active
immunotherapies: AADvac1 (Novak et al., 2017) and ACI-35
(Theunis et al., 2013); and seven passive immunotherapies:
R07105705 (Lee et al., 2016), Zagotenemab (LY3303560) (Alam
et al., 2017), BIIB076 (Czerkowicz, 2017), ABBV-8E12 (C2N
8E12) (Yanamandra et al., 2015), Gosuranemab (BIIB092) (Boxer
et al., 2019), UCB0107 (Alzforum, 2018), and JNJ-63733657
(Alzforum, 2018). While there are several clinical trials ongoing
(Long and Holtzman, 2019), complementary approaches
targeting alternative pathways still need to be explored.
Over the last two decades, several pieces of evidence suggest
that some elements of purinergic signaling, in particular P2X7R,
might contribute to AD pathology (Parvathenani et al., 2003;
McLarnon et al., 2006; Ryu and McLarnon, 2008; Sanz et al.,
2009; Delarasse et al., 2011; Diaz-Hernandez et al., 2012; Sanz
et al., 2014; Martin et al., 2019; Martinez-Frailes et al., 2019).
The first observation of the possible involvement of P2X7R
in AD was based on the upregulation of this receptor in
microglial cells surrounding senile plaques both in human
AD patients and animal models mimicking AD (Parvathenani
et al., 2003; McLarnon et al., 2006; Ryu and McLarnon,
2008). Genetic evidence also provided an association between
P2X7R and AD, finding a negative correlation among P2X7R
489C>T polymorphism and AD (Sanz et al., 2014). Later
studies supplied additional proofs supporting the involvement
of P2X7R in the amyloidogenic APP processing (Delarasse
et al., 2011; Diaz-Hernandez et al., 2012), synaptic dysfunction
(Lee et al., 2011; Saez-Orellana et al., 2016, 2018; Goncalves
et al., 2019), oxidative stress (Parvathenani et al., 2003; Lee
et al., 2011; Zhang et al., 2015), and neuroinflammation
(Kim et al., 2007; Sanz et al., 2009; Chiozzi et al., 2019; Martin
et al., 2019; Martinez-Frailes et al., 2019), associated to AD
(Figure 1). Supporting the potential therapeutic role of P2X7R,
others groups demonstrated that its pharmacological blockade
or genetic depletion leads to a significant improvement both
symptomatology and neuropathology in AD animal models
(Ryu and McLarnon, 2008; Diaz-Hernandez et al., 2012;
Chen et al., 2014; Martin et al., 2019). In this review,
we are going to examine the different findings supporting
a critical role of P2X7R in the regulation of molecular
mechanisms underlying AD.
P2X7R
P2X receptors are plasma membrane ligand-gated ion channels,
whose activation causes a selective influx of small cations (Na+,
Ca2+) and K+ efflux from cells (Nicke et al., 1998; Hatorri and
Gouaux, 2012; Samways et al., 2014). Similar to other members
of P2X family, P2X7 subunit has two transmembrane domains
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FIGURE 1 | Schematic illustration summarizing the pieces of evidence accumulated over the past years indicating that P2X7R plays a central role in the different
physiopathological processes associated with Alzheimer’s disease. The outer circular arrows illustrate a chain of interconnected and mutually influenced pathological
processes associated with AD. Inner arrows represent the relationships found between P2X7R and these pathological processes, summarizing the studies
discussed in the present review. Briefly, P2X7R modulates amyloid APP processing, and it is postulated as a neuroinflammation triggering factor. Upregulated P2X7R
expression in AD patients and different AD and neuroinflammation mouse models give it a key role in disease progression. Besides, P2X7R also contributes to
neuronal loss and synaptic alterations, oxidative stress; inflammasome assembling; and altered microglial function, being all of them processes contributing to AD
progression, as described in the present review.
linked by a large extracellular domain (Nicke et al., 1998).
These subunits present a dolphin-shaped structure with the
transmembrane helices and the extracellular region similar to the
tail and the body, respectively (McCarthy et al., 2019). Among all
P2X receptors, P2X7 is the only one found as a homotrimer in
physiological models. Human P2X7R protein is a 595 amino acid
protein encoded by the P2RX7 gene located on chromosome 12
(12q24.31 locus) spanning 53,733 bases (NCBI, 2017). Alternative
splicing takes place during gene’s transcription and may give rise
to at least 11 different splice variants of P2X7R, described to date
(Rassendren et al., 1997; Cheewatrakoolpong et al., 2005; Skarratt
et al., 2005, 2020; Feng et al., 2006; Adinolfi et al., 2010; Sluyter
and Stokes, 2011). Specific features of full length P2X7 protein
include a large C-terminal domain (Virginio et al., 1999); low
sensitivity to its native ligand (ATP) and sensitive to extracellular
divalent cations (Surprenant et al., 1996). Different intracellular
mediators have been associated with P2X7R activation
such as calcium calmodulin kinases II (Diaz-Hernandez
et al., 2008), nuclear factor kappa-light-chain-enhancer
(NFκB) (Ferrari et al., 1997), ROS/NOS formation
(Hewinson and MacKenzie, 2007), glycogen synthase kinase-3
(GSK3) (Diaz-Hernandez et al., 2008), phospholipase D
(Humphreys and Dubyak, 1996), inflammasome “NACHT,
LRR, and PYD domains-containing protein 3” (NLRP3)
(Franceschini et al., 2015). However, sustained activation of
P2X7R by high ATP concentrations may induce apoptosis
or necrosis in some cellular lineages (Virginio et al., 1999;
Delarasse et al., 2009).
Although its specific distribution in the CNS remains
debated (Miras-Portugal et al., 2017; Illes et al., 2017), P2X7R
expression has been reported in almost all cellular lineages
making up the brain tissue, including astrocytes, microglia,
oligodendrocytes, and neurons (Matute et al., 2007; Miras-
Portugal et al., 2017). Interestingly, P2X7R has also been
related to several physiological events including neuronal
differentiation (Messemer et al., 2013; Tsao et al., 2013;
Glaser et al., 2014; Fumagalli et al., 2017), axonal growth
and branching (Diaz-Hernandez et al., 2008), presynaptic
regulation and neurotransmitter release (Sperlagh et al., 2002;
Miras-Portugal et al., 2003; Leon et al., 2008), microglial
activation, migration, and proliferation (Sanz et al., 2009;
Rigato et al., 2012; Martinez-Frailes et al., 2019), glial and
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microglial phagocytosis (Ni et al., 2013; Gu and Wiley, 2018;
Martinez-Frailes et al., 2019).
Upregulation of P2X7R in Alzheimer’s
Disease
One of the initial pieces of evidence suggesting a possible
involvement of P2X7R in AD was the increased P2X7R
expression found in microglial cells surrounding amyloid
plaques both in AD patients and different AD mouse models
(Parvathenani et al., 2003; McLarnon et al., 2006). Later
studies using two different mouse models of AD based on
the transgenic expression of human APP (APP/PS1 mice and
J20 mice, thoroughly described below) confirmed that P2X7R
upregulation in activated microglial was parallel with AD
progression (Lee et al., 2011; Martinez-Frailes et al., 2019).
Another study showed that 9-months-old P301S tau mice,
overexpressing mutant human protein tau (MAPT P301S) driven
by the mouse prion protein (Prnp) promoter (Yoshiyama et al.,
2007), show a higher cerebral binding of a radiotracer for
P2X7R, [123I]TZ26019, than their corresponding WT control
mice. Subsequent analysis revealed that P2X7R was mainly
found in hippocampal astrocytes in P301S mice (Jin et al.,
2018). However, no robust data about the molecular mechanism
causing the glial P2X7R upregulation were provided in these
studies. Although astroglial activation is a histopathological mark
associated with tau-induced toxicity, including AD, little is know
about how this cellular type contributes to tau-induced toxicity
(Forrest et al., 2019). Considering the critical role of P2X7R on
the astrocytic function (Miras-Portugal et al., 2017), additional
studies to determinate whether astroglial P2X7R is contributing
to tau-associated pathology should be done.
A recent study reported that PS2 deficient mice are
most sensitive to Aβ-induced neuroinflammation due to the
upregulation of P2X7R in both glial and neuronal cells in a
transcription factor Sp1 (SP1)-dependent manner (Qin et al.,
2017). Taking into account that SP1 is a transcription factor
promoting P2X7R expression (Garcia-Huerta et al., 2012) and
that neuroinflammation causes SP1 upregulation via activation
of intracellular kinases cascades (Citron et al., 2008), it is
reasonable to think that dysregulation of SP1 may be the factor
causing P2X7R upregulation detected in AD. Supporting the
involvement of SP1 in the molecular mechanisms underlying
Aβ-induced toxicity in AD, a significant increase in both SP1
messenger and protein levels was found in the cortex of AD
patients and in two mouse models of AD, APP/PS1 mice and
Tg2576 mice (Citron et al., 2008). These mice overexpress human
APP containing the Swedish mutation under the control of the
hamster prion protein promoter (Hsiao et al., 1996). In this line,
it was also reported that SP1 as a transcription factor is able
to regulate the expression of both APP and tau proteins (Izumi
et al., 1992; Heicklen-Klein and Ginzburg, 2000). However, the
potential role of SP1 as a therapeutic target in AD was put in
doubt after the observation that its sustained pharmacological
inhibition, induced by a selective SP1 inhibitor (mithramycin),
caused a significative memory deficit and increased the Aβ1−42
and Aβ1−40 ratio (Citron et al., 2015). These results indicate
that global inhibition of SP1 contributes to neurodegeneration
rather than plays a protective role. These side effects could be
due to the wide range of different off-target genes regulated
by SP1 transcription factor (Bird, 1986; Larsen et al., 1992;
Siegfried et al., 1999).
P2X7R in Amyloidogenic APP Processing
Longitudinal studies combining cognitive assessment, PET
analysis, and the measurement of pathognostic molecules from
the CSF of eFAD and late-onset AD patients showed an early
deposition of Aβ in the precuneus and other cortical areas
10–12 years before first AD symptoms appear (Vermunt et al.,
2019). Based on these findings, it is currently accepted that Aβ
accumulation represents the initial event triggering the disease.
Preceding the onset of cognitive impairment, following the
initial Aβ accumulation, a sequential tau accumulation can be
observed (Morris et al., 2009; Bateman et al., 2012; Fagan et al.,
2014; Gordon et al., 2018; Hanseeuw et al., 2019). However, the
existence of cases in which senile plaque burden was detected
in brains collected from healthy individuals with no dementia
(Shankar et al., 2008; Perez-Nievas et al., 2013), put in doubt
that Aβ is the only factor triggering AD. As described above,
although APP protein may be processed by both amyloidogenic
and non-amyloidogenic pathways in the CNS (Hardy and
Selkoe, 2002), it is postulated that in healthy brains APP is
preferably cleaved via the non-amyloidogenic pathway (Tyler
et al., 2002). Nevertheless, deregulation in this balance might
favor amyloidogenic processing, leading to Aβ accumulation
(Stockley and O’Neill, 2008).
Different studies using both in vitro and in vivo approaches
postulated that P2X7R might be one of the factors controlling
APP processing (Delarasse et al., 2011; Leon-Otegui et al.,
2011; Darmellah et al., 2012; Diaz-Hernandez et al., 2012).
APP protein can be processed in two different ways. The
amyloidogenic pathway is mediated by β- and γ-secretase and
results in the generation of extracellular sAPPβ, Aβ-peptides,
and the intracellular C-terminal fragment C99. On the other
hand, the non-amyloidogenic pathway involves the α-and γ-
secretases and results in the generation of an intracellular
C-terminal fragment, called C88, extracellular peptides sAPP and
the P3 peptides (Selkoe, 2001). Preliminary studies, using mouse
neuroblastoma cells (N2a) expressing human APP, reported
that BzATP-induced P2X7R activation stimulates the release of
sAPP in a mitogen-activated protein kinases (MAPK)-dependent
manner. This release was inhibited by selective P2X7R knock-
down with siRNA and by specific P2X7R antagonists (Delarasse
et al., 2011). In a subsequent study, this group reported that
Ezrin/Radixin/Moesin (ERM) are required for P2X7R-dependent
processing of APP (Darmellah et al., 2012). However, another
group, using two different cell lines, found that the inhibition
and not the activation of native or overexpressed P2X7R increases
α-secretase activity (Leon-Otegui et al., 2011; Diaz-Hernandez
et al., 2012). In vivo studies confirmed that pharmacological
blockade of P2X7R reduces size and number of hippocampal
senile-plaques in 8-months-old J20 mice (PDGF-APPSw,Ind).
These mice overexpress human APP with the Swedish (APP
KM670/671NL) and Indiana (APP V717F) mutations under the
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control of platelet-derived growth factor subunit B (PDGFB)
promoter (Mucke et al., 2000). This beneficial effect was
GSK3-dependent (Diaz-Hernandez et al., 2012). To shed light
on these contradictory results, a recent study generated P2X7R
deficient APP/PS1 mice. APP/PS1 mice express a chimeric
mouse/human APP and human PSN1, with the deletion of exon 9
found in eFAD patients, under the mouse prion protein promoter
(APP/PSN1/P2X7−/−) (Jankowsky et al., 2004). Results obtained
in this study confirmed that genetic depletion of P2X7R leads
to a significant reduction in the number of senile plaques in
10-months-old APP/PS1 mice. This decrease was accompanied
by a drastic decreasing in Aβ peptides levels and rescue of
the cognitive deficit developed by APP/PS1 mice (Martin et al.,
2019). All previous data suggest that dysregulation of P2X7R
signaling may be one of the factors promoting APP amyloid
processing in AD.
P2X7R in Neuroinflammation Associated
With AD
It is widely known that accumulation of Aβ in senile plaques
initiates the inflammatory process on AD (McGeer et al.,
2000) and favors the activation of the microglial cells
around them (Selkoe, 2002). In these cells, the P2X7R
upregulation suggests its involvement in microglia cells
mediated-neuroinflammatory response on AD (Parvathenani
et al., 2003; McLarnon et al., 2006). In the following sections,
we will describe how the upregulation of P2X7R in microglial
cells contributes to neuroinflammation and how this impacts on
microglial functionality.
P2X7R in Inflammasome Activation
Microglial cells have dual effects on AD progression. On one
side, they promote a decrease in Aβ accumulation by stimulating
its phagocytosis, clearance, and degradation. On the other
side, chronic microglial activation leads to the release of pro-
inflammatory cytokines that can contribute to the neuronal
loss (Wang S. et al., 2015; Wang W. Y. et al., 2015). This dual
effect may be caused by the activation of microglial cells in two
subsets that present different molecular phenotype: the classical
(M1) or the selective (M2) activated state (Czeh et al., 2011;
Thawkar and Kaur, 2019). M1 state-activated microglia cells
promote the release of pro-inflammatory cytokines, playing a
pivotal role in the defense against pathogens or tumor cells.
M2 state-activated microglia cells secrete anti-inflammatory
cytokines promoting tissue repairment (McGeer et al., 2000;
Walker and Lue, 2015; Wang W. Y. et al., 2015). However,
this is a simplified classification since and microglia cells may
acquire other activation states (Ransohoff, 2016). At this regard,
a recent genome-wide transcriptome analysis of microglia from
models of different neurodegenerative disease has allowed to
identify a new disease-associated microglia (DAM) phenotype
(Krasemann et al., 2017; Song and Colonna, 2018). DAM, in
addition, to express genes characteristic in both classical M1
macrophages and classical M2 macrophages, also express others
related to the interferon response, stress response, lysosomal
function, and lipid metabolism (Song and Colonna, 2018).
One of the first molecules directly linked to activation of DAM
was TREM2, a single-immunoglobulin-domain-containing
macrophage-specific receptor. Interestingly, recent studies have
postulated that this protein plays a central role in the onset and
the development of AD because microglia surround and enclose
neuritic plaques in a TREM2-dependent manner (Wang Y. et al.,
2015; Meilandt et al., 2020).
Data obtained from studies using lipopolysaccharide
(LPS)-induced neuroinflammation animal model has
contributed clarify the role of microglial cells in
neuroinflammation (Boche et al., 2013). LPS activates
Toll-like receptor 4 (TLR4) after binding LBP (LPS-binding
protein), an intracellular signaling pathway that leads to the
activation of nuclear factor NF-kB by a Myeloid differentiation
primary response protein MyD88 (MyD88)-dependent
mechanism. When activated, NF-kB translocates to the
nucleus, binding the DNA, and promoting the transcription of
proinflammatory mediators, such as proinflammatory cytokines
like pro-interleukin-1 beta (pro-IL1β), pro-interleukin-18
(pro-IL18), and NLRP3 inflammasome (Takeda and Akira, 2004;
Venigalla et al., 2016). Activation of this intracellular pathway
is a priming event. However, to trigger NLRP3 inflammasome,
a cytosolic multiprotein oligomer responsible for the activation
of inflammatory responses, a subsequent signal causing a
decrease K+ levels in the cytosolic microenvironment is required
to facilitate the oligomerization of NLRP3. Afterward, the
inflammasome recruits the apoptosis-associated speck-like
protein (ASC) and the procaspase-1 (another apoptosis-related
protein), leading to the secretion of IL1β and IL18 (Petrilli et al.,
2007; He et al., 2016). Several studies have shown that ATP, found
at high extracellular concentrations following insults (Burnstock,
2008, 2016) or released by Aβ peptide (Kim et al., 2007; Sanz
et al., 2009; Saez-Orellana et al., 2018; Goncalves et al., 2019),
may be one of the signals promoting NLRP-inflammasome
assembling and subsequent IL1β processing (Laliberte et al.,
1999; Perregaux et al., 2000; Ye et al., 2013). Interestingly,
recent studies have reported that NLRP3 activation may
also induce tau hyperphosphorylation and aggregation in
an IL-1β-dependent manner (Ising et al., 2019). Initially,
in vitro studies using microglial cells isolated from rat brains
showed that fibrillar Aβ1−42 peptide-induced ATP-release
by P2X7R-dependent mechanism (Kim et al., 2007). Later,
using both in vitro and in vivo approaches, it was suggested
that Aβ-induced microglial activation requires the activation
of P2X7R via an autocrine/paracrine stimulatory loop (Sanz
et al., 2009). Additional research revealed that Aβ causes via a
P2X7R-dependent mechanism NF-kB activation and NLRP3
inflammasome expression in microglial cells (Chiozzi et al.,
2019). Since pretreatment of cultured microglial cells with
potassium chloride (KCl), avoided microglial NRLP3 activation
(Gustin et al., 2015), it is reasonable to postulate that efflux of K+
induced by P2X7R activation is the mechanism by which P2X7R
promotes NRLP3 activation in microglial cells. These studies are
suggesting that P2X7R/NLRP3/Caspase1 signaling is a crucial
pathway in the inflammasome activation once the microglial cell
is primed. In accordance with this hypothesis, Martinez-Frailes
et al. (2019) found that upregulation of P2X7R in microglial
cells takes place in advanced and late stages of AD, but not
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in the early stages, when the microglial priming has not yet
occurred, and there is a reduced number of senile plaques. In line
with this concept, inflammasome activation in APP/PS1 mice
occurs in an age- and Aβ deposition-related fashion (Heneka
et al., 2013). Recent studies have also proposed the involvement
of P2X7R in the initial microglial priming induced by serum
amyloid A (SAA) protein via TLR4 activation (Niemi et al.,
2011; Facci et al., 2018). SAA is a high-density apolipoprotein
generated in the liver and released to the systemic circulation,
where it is mainly found associated with HDL, in response to
inflammation, reaching different organs including the brain
(Gabay and Kushner, 1999). In AD patients, SAA co-localized
with cerebral amyloid Aβ-peptide deposits (Kindy et al., 1999)
and it is present in high levels in CSF of AD patients (Miida et al.,
2006). In cortical microglial cells isolated from rat brain, it was
reported that SAA causes microglial priming and inflammasome
activation in a P2X7R-dependent manner (Facci et al., 2018).
As, in recent years, it has been suggested that the control
or reduction of the chronic neuroinflammation associated with
neurodegenerative diseases may be an efficient therapeutic
strategy (Beamer et al., 2016; Ribeiro et al., 2019; Thawkar and
Kaur, 2019). Therefore, the regulation of neuroinflammation
associated with AD by P2X7R is gaining relevance as a possible
remedial to fight these disorders. This affirmation is based on
the concept that chronic neuroinflammation may contribute to
neurodegeneration by promoting the release of proinflammatory
cytokines, increasing the permeability of blood–brain barrier
(BBB) favoring the recruitment of systemic immune effectors
cells and causing a synaptic dysfunction leading to neuronal
loss (O’Callaghan et al., 2008; Thawkar and Kaur, 2019). In
agreement with this, it has been reported that pharmacological
blockade or knocking out the P2X7R in different AD mouse
models have positive effects by reducing neuroinflammation (Ryu
and McLarnon, 2008; Chen et al., 2018; Martin et al., 2019). Initial
studies reported that in vivo pharmacological inhibition of P2X7R
by Brilliant Blue G (BBG) attenuated inflammatory response and
diminished leakiness of BBB induced by intracerebroventricular
(i.c.v.) injection of Aβ1−42 peptide in rat hippocampus (Ryu and
McLarnon, 2008). In accordance, later study revealed that in vivo
inhibition of P2X7R by i.p. administration of BBG prevented
the spatial memory impairment and cognitive deficiency in
an AD mouse model (Chen et al., 2014). Another study
reported that i.c.v. administration of oxidized ATP (o-ATP), a
P2X7R antagonist, attenuated microglial activation and neuronal
damage induced by i.c.v. administration of LPS (Choi et al.,
2007). On the other hand, a sustained P2X7R inhibition by
BBG did not modify either the number or the morphology of
astroglia or microglial cells. Although, the specific treatment,
did reduce IL1β secretion and promote the non-amyloidogenic
APP processing in the hippocampus of young J20 mice
(Diaz-Hernandez et al., 2012). Moreover, a recent study has
reported that APP/PS1/P2X7R deficient mice present smaller
cognitive deficit and better synaptic plasticity than APP/PS1
mice. Furthermore, knocking out P2X7R reduces Aβ-induced
chemokines release in glial cells, especially C-C motif chemokine
3 (CCL3), which is related to the pathogenic CD8+ T-cells
recruitment (Martin et al., 2019). All these studies suggest that
BBB permeable compounds and selective P2X7R antagonists
might be considered as good therapeutic drugs to treat chronic
neuroinflammation associated with AD.
P2X7R in Microglial Migration
During neuroinflammation, extracellular ATP and other
nucleotides seem to act as “find me” and “eat me” signals (Di
Virgilio et al., 2009). This hypothesis is based on the fact that
extracellular ATP is capable of inducing morphological changes
in microglial cells favoring their rapid migration toward local
brain injury (Davalos et al., 2005). Initial studies indicated
that extracellular purines modulate the microglial migration
through their specific metabotropic receptors P2Y12, P2Y1,
or P2Y6 (Inoue, 2008; De Simone et al., 2010; Bernier et al.,
2013; Langfelder et al., 2015). However, new findings also
suggest the involvement of ionotropic purinergic receptors
in this phenomenon (Martinez-Frailes et al., 2019). Using
in vitro and in vivo approaches, Martinez-Frailes et al. (2019)
have recently confirmed that ATP-induced P2X7R activation
promotes microglial migration. These findings might explain
why there is an enrichment on P2X7R positive microglial cells
around the senile plaques both in AD mouse models and in
postmortem brain samples from AD patients (Parvathenani
et al., 2003; McLarnon et al., 2006; Lee et al., 2011; Martinez-
Frailes et al., 2019). In this line, it reported that P2X7R
upregulation in the microglial cell increases in parallel to the
incidence of senile plaques (Lee et al., 2011). Moreover, in vivo
blockade of P2X7R by BBG also caused a reduction of GSK3
activity in P2X7R-expressing microglial cells, by increasing
p-GSK3 levels (Diaz-Hernandez et al., 2012). Other in vitro
studies using BV-2 mouse microglial cells or brain slices also
confirmed that GSK3 inhibitors significantly reduced the
migratory capacity of microglial cells (Yuskaitis and Jope,
2009). All these findings suggest that P2X7R activation not only
promotes NLRP3 inflammasome assembling but also stimulates
microglial migration.
P2X7R in Microglial Phagocytosis
Another microglia feature that has been related to purinergic
signaling is its phagocytic capacity. First studies suggested that
purinergic compounds modulated the phagocytic capacity of
microglial cells through the metabotropic P2Y6 receptor (Inoue,
2008). However, recent studies have provided additional data
indicating that other purinergic receptors may also regulate
this microglial function, as P2X7R. In this line, in vitro
studies using mouse primary microglial cells isolated from the
hippocampus demonstrated that both P2X7R genetic depletion
using specific RNAi and its pharmacological inhibition by BBG
favors microglial phagocytosis of fibrillar Aβ1−42 and decreases
IL1β secretion capacity. In this line, the enrichment of the
culture medium with IL1β reduced the microglial Aβ1−42
phagocytosis (Ni et al., 2013). Additional evidence on P2X7R
mediated-regulation of microglial phagocytosis has also been
provided by later studies (Janks et al., 2018; Martinez-Frailes
et al., 2019). Using both in vitro and in vivo approaches, it has
been found that GSK 1482160A, a selective P2X7R inhibitor,
significantly increased the phagocytosis of 2 µm diameter
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fluorescence microspheres by microglial cells expressing P2X7R
(Martinez-Frailes et al., 2019). Accordingly, other in vitro studies
using cultured primary human microglial cells confirmed that
P2X7R activation induced by 300 µM Bz-ATP decreased the
phagocytic capacity of microglial cells. That effect was prevented
when they used the selective P2X7R antagonist 50 µM A438079
but not by the selective P2X4R antagonist Bx430 (Janks et al.,
2018). In agreement with these findings, ATP induced P2X7R
activation causes cytoskeleton changes in microglial, reducing
their phagocytic capacity (Fang et al., 2009). In this line,
and taking into account the important role that microglial
phagocytosis plays in the removing of senile plaques, it is to
worth highlighting that, both in the hippocampus of J20 mice
and in postmortem cortical samples from human AD patients,
the majority of microglial cells in contact with senile plaques
did not express P2X7R. Furthermore, the percentage of microglia
expressing P2X7R inside extracellular Aβ deposits remains
constant along the AD progression, in opposition to the rising of
the total number of microglial cells (Martinez-Frailes et al., 2019).
Interestingly, in human microglial cells, BzATP-induced P2X7R
activation reduced its phagocytic capacity and produced mature
caspase-1 by activating the inflammasome, revealing a close
relationship between both events (Janks et al., 2018). Supporting
this concept, the NLRP3 inflammasome inhibitor, MCC950,
stimulates Aβ phagocytosis in vitro and reduces the number
of senile hippocampal plaques in APP/PS1 mice, causing an
improvement in their cognitive function (Dempsey et al., 2017).
Indeed, double transgenic mice resulting from the crossbreed of
APP/PS1 mice and NLRP3−/− or caspase-1−/− (CASP1) mice
exhibited a significant reduction in the loss of spatial memory
and an enhanced Aβ clearance, compared with APP/PS1 mice.
Furthermore, the NLRP3 inflammasome deficiency promoted
the switch of microglial cells to M2 state, resulting in decreased
deposition of Aβ in APP/PS1 mice (Heneka et al., 2013). This
evidence strongly suggests that therapeutic strategies focusing
either on direct inflammasome inhibition or on avoiding its
assembling by blocking P2X7R, might be efficient for reducing
neuroinflammation and promoting Aβ phagocytosis in AD.
P2X7R in Oxidative Stress Associated
With AD
Oxidative stress is a condition where the generation of reactive
oxygen species (ROS) exceeds the capacity of antioxidative
mechanisms of the cell (Zuo et al., 2015). High levels of
ROS are commonly detected in the brain of patients suffering
from different neurodegenerative diseases, including AD (Albers
and Beal, 2000; Sebastian-Serrano et al., 2019). Although
these species cannot trigger the neurodegenerative disease on
their own, they might favor its progression by promoting
the oxidative damage and interacting with mitochondria (Dias
et al., 2013). Thereby, accumulation of ROS might cause
mitochondrial alterations, resulting in increased ROS production
and consequent mitochondrial dysfunction, favoring the disease
progression. Accordingly, the content of ATP in the tissue is
reduced in parallel to the disease progression in APP/PS1 mice.
This fact is suggesting that this decline is caused by mitochondrial
dysfunction provoked by ROS accumulation (Zhang et al.,
2015). Moreover, Aβ can lead to ROS production, in particular,
hydrogen peroxide (H2O2), that causes the damage of proteins,
lipids, and nucleic acids (Eckert et al., 2003). Several pieces
of evidence point to the fact that P2X7R may be the primary
receptor involved in the generation of H2O2 by activating
microglial cells (Nuttle and Dubyak, 1994). Stimulation of
isolated microglial cells from rat brain with ATP or BzATP,
induced O2− release in NADPH oxidase activation-dependent
mechanism. Furthermore, inhibition of phosphatidylinositol
3 kinase, a kinase involved in GSK-3 signaling, attenuated
BzATP-induced H2O2 release, preventing microglial-induced
cortical death (Parvathenani et al., 2003). In vitro studies reported
that fibrillar Aβ1−42 causes ROS production generated via P2X7R
activation induced by ATP released from rat microglial cells in an
autocrine manner (Kim et al., 2007; Liu et al., 2020). Additional
studies revealed that P2X7R positive microglial cells surrounding
senile plaques express the catalytic NADPH subunit (gp91phox)
and produce ROS species in APP/PS1 mice. Hence, P2X7R
upregulation in microglial cells may result in excessive ROS
production induced by Aβ via P2X7R, which contributes to the
synaptic toxicity associated with the early stages of AD (Lee et al.,
2011). Recently, a study using P2X7R-deficient microglial cell
line (N13R) has demonstrated that Aβ-induced mitochondrial
toxicity requires P2X7R in microglial cells (Chiozzi et al.,
2019). In agreement with the antioxidative effect of P2X7R
antagonists, in vivo administration of selective P2X7R antagonist
A438073, avoided ROS production and oxidative DNA damage
induced by P2X7R activation in spinal cord dorsal horn neurons
(Munoz et al., 2017).
P2X7R in Synaptic Dysfunction and
Cellular Death in AD
Another major hallmark of AD is the extensive loss of synapses
correlating with cognitive impairment (Lansbury, 1999). One of
the most robust pieces of evidence indicating that Aβ deposits
contribute to synaptic loss is the observation that a degree of
synaptic loss is more evident in the proximity of the senile plaques
(Lanz et al., 2003). Initial studies postulated that the synaptic
loss detected in APP/PS1 mice was due to the dysfunction and
collapse of the excitatory synapses. This fact was caused by the
interaction of the soluble Aβ peptide oligomers coming from
the surrounding plaques with these synaptic contacts (Koffie
et al., 2009). However, the molecular mechanism by which Aβ
alters synaptic transmission causing a subsequent synaptic loss
remains unclear (Brody and Strittmatter, 2018). One hypothesis
is that Aβ may interact directly with neuronal synaptic receptors
such as metabotropic glutamate receptor 5 mGluR5 (Um et al.,
2013), or α7 nicotine acetylcholine receptor α7nAChR (Wang
et al., 2000). Others postulate that microglial cells activated
by Aβ are responsible for assaulting the synapses (Hong
et al., 2016). Nevertheless, new evidence suggests that synaptic
dysfunction associated with AD may be due to dysregulation of
P2X receptors mediated neurotransmission; dysregulation that
may be triggered by increased extracellular ATP concentration
induced by Aβ (Chen et al., 2014; Saez-Orellana et al., 2016,
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2018; Goncalves et al., 2019). Supporting this hypothesis,
higher K+ depolarization-induced ATP release was found in
hippocampal nerve terminals isolated from i.c.v. Aβ1−42-treated
mice (Goncalves et al., 2019). According to this, pharmacological
blockade of P2X7R prevents the increase in the current
frequency of the excitatory synapse induced by oligomeric
Aβ when binding to excitatory neurons (Saez-Orellana et al.,
2016, 2018). Furthermore, pharmacological inhibition of
P2X7R prevented Aβ-induced loss of filopodia and spine
density in cultured hippocampal neurons (Chen et al., 2018).
Other studies have provided additional evidence suggesting
that P2X7R-mediated ROS production in Aβ-stimulated
microglial is one of the mechanisms explaining oligomeric
Aβ-mediated synaptic-toxicity in APP/PS1 mice (Lee et al.,
2011). In accordance with this toxic effect, BzATP-induced
P2X7R activation caused microglia-induced cortical cell death
(Parvathenani et al., 2003). Choi et al. (2014) reported similar
results, observing that in vivo P2X7R blockade by o-ATP reduces
the number of positive caspase-3 neurons in LPS-injected brains
(Choi et al., 2007). In concordance with the involvement of
P2X7R in the synaptic-toxicity induced by Aβ, P2X7R deficiency
rescued the synaptic alterations and LTP deficits detected in
APP/PS1 mice (Martin et al., 2019). Interestingly, it was reported
that, contrary to what was observed in microglial cells, neuronal
P2X7R transcription is reduced in J20 mice both in early and
advanced stages. This points to the fact that this phenomenon
could be an adaptive physiological response to avoid or at least
lessen the neuronal loss associated with AD. However, the loss of
this capacity may contribute to the exacerbation of neuronal loss
in the late stages of AD (Martinez-Frailes et al., 2019).
INDUCED PLURIPOTENT STEM CELLS
IN AD RESEARCH
The currently available knowledge regarding AD is mostly based
on results acquired from post-mortem patient samples or animal
models mimicking the disease. However, because human brain
tissue is extremely hard to obtain, especially if there is a need for
early-onset materials, a need for a human-derived in vitro system
arose. Thus, the Nobel Prize awarded induced pluripotent stem
cell (iPSC) technology that allows the genetic reprogramming
of mature somatic cells into pluripotent stem cells (PSCs)
(Takahashi et al., 2007) became widely utilized.
The differentiation of cells from patient-specific iPSCs
provides valuable insight into specific molecular phenotypes
of neurodegenerative diseases (McKinney, 2017) because
the cells possess the complete genetic background of the
patient. Moreover, healthy individuals’ derived iPSCs can
be genetically modified to introduce disease-specific genetic
patterns (Ortiz-Virumbrales et al., 2017).
Many neurodegenerative disease models are available to date.
For example, AD patient-derived iPSCs are being used by many
research groups (Israel et al., 2012; Kondo et al., 2017; Ochalek
et al., 2017; Sullivan and Young-Pearse, 2017; Arber et al., 2019;
Chang et al., 2019).
Focusing on AD research, the use of iPSC-derived cells has
helped to discover new pathological mechanisms underlying
AD pathology. For instance, describing for the first time
an autophagic dysfunction due to lysosomal depletion and
suggesting that modifying the lysosomal biogenesis could present
a novel therapeutic intervention (Lee et al., 2014). Besides,
iPSC-derived cells responded very differently to drug treatments
than APP-overexpressing cell lines and thus demonstrated that
it can be a better option for preclinical screening of compounds
(Liu et al., 2014). iPSC-models have helped to prove that
β-secretase has a higher affinity for neuregulin (NRG1) than
for APP, which means that it might be possible to inhibit
Aβ production via BACE1 processing without affecting BACE1
interactions with its other substrates (Ben Halima et al., 2016).
Importantly, iPSC-based systems are suitable for compound
screening. A correlation between CSF profiles from patients and
their own Aβ secretome in the differentiated neuronal cultures
was found, showing the relevance of iPSC derived systems in
AD modeling (Kondo et al., 2017). In AD iPSC-derived neurons,
constitutional metabolic changes in ROS production without
mitochondrial fission and fusion proteins damage have been
described. These findings suggest that increased ROS production
might have a more important role in amyloid- and tau-pathology
than previously anticipated (Birnbaum et al., 2018). Furthermore,
findings in these models shown tau protein species propagation
patterns where tau oligomers, but not monomers, induced
accumulation of pathological, hyperphosphorylated tau in
human neurons (Usenovic et al., 2015). Therefore, it is realistic
to expect that this technology will provide valuable insights into
the P2X7R research field in the near future.
Application of 3D cell cultures will help to model more
reliably the brain tissue cell interactions and microenvironment,
including gradients of signaling molecules (Zhang et al.,
2014). Particularly for neurodegeneration research, 3D systems
promote the formation of specific neuronal cell types with
complex interactions and development of AD pathologies,
taking into account gradients of signaling molecules such as
ATP and the subsequent cellular responses within the tissue
(Mungenast et al., 2016).
CONCLUDING REMARKS
Due to the fact that many anti-amyloid clinical trials have
failed, Aβ-directed therapies focusing on the reduction of
parenchymal Aβ and amyloid deposits in AD brains have been
put in doubt (Long and Holtzman, 2019). Many strategies were
tested: active and passive immunization, secretase inhibitors
or drugs avoiding amyloid aggregation, but none of them
was effective in modifying the disease course in symptomatic
AD patients (Hara et al., 2019). However, there are still
ongoing active Phase III clinical trials based on monoclonal
antibodies against Aβ, new anti-inflammatory molecules and
to induce an active immunization, whose results could be
concluded later (Long and Holtzman, 2019). As results from
studies using animal models, mimicking AD pathology are
strongly suggesting that Aβ is the triggering disease factor,
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perhaps, amyloid-direct therapies would be more useful to treat
preclinical cases. Moreover, the vast number of symptomatic
AD patients require the urgent development of new therapeutic
strategies. In recent years, strategies focused on modulating
neuroinflammation, or microglial response have taken strength.
So, taking this into account, selective P2X7R antagonists might
be considered as potential therapeutic drugs. In addition to
reducing the Aβ burden, promoting the non-amyloidogenic
APP and processing, P2X7R antagonists have also shown
anti-inflammatory, neuroprotective, and antioxidant effects,
which might counter the pathological conditions associated with
AD. Although human iPSC-based studies have not yet reported
on the expression of P2X7R in the in vitro models, either on
iPSC-derived neurons or astrocytes, the increasing number of AD
patient-derived iPSC disease models will promote the emergence
of such investigations toward potential therapeutic targets.
Indeed, taking into account the complex pathological state found
in AD and other neurodegenerative diseases, nowadays it is
postulated that many factors together play a role in facilitating
the progressive and detrimental neurodegenerative process. Since
major biological systems of the human body are involved—such
as the nervous system itself, the immune system, the endocrine
system, possibly the digestive system (Jiang et al., 2017; Vogt
et al., 2017) and perhaps others, currently unknown features and
mechanisms, it is extraordinarily challenging to target only one
of the systems or pathological processes in the attempt to cure
neurodegenerative diseases. Perhaps the time has come to rethink
the therapeutic strategies to treat these diseases, in a way where
multiple mechanisms could be pharmacologically targeted at the
same time, as long as the individual interventions could add
up and lead to the elimination of the progression or even the
symptoms of dementia. As we discussed in this review, P2X7R
may be an excellent target for this multi-target therapy.
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